결핵연구원

The risk of group infections and pandemics due to emerging viruses is increasing. Cases of group outbreaks of emerging infectious diseases, such as the SARS in 2005, influenza A in 2009, Ebola virus in 2014, MERS in 2015, and COVID-19 in 2019, representativly.
Vaccines are the most basic and effective means to prevent the spread of infectious diseases in pandemics and group outbreaks of emerging infectious diseases. Effective response to the occurrence of emerging infectious diseases requires vaccine development and production to be completed before the maximum epidemic of the infectious disease, with development completed within six months after onset and usage approval within one year.
KIT is developing a rapid response vaccine platform using recombinant BCG to respond to group outbreaks and pandemics of emerging infectious diseases. Including a four-year development period from 2021 to 2024, trials are underway to develop a rapid response vaccine that can immediately respond to emerging infectious diseases by screening and producing antigens from the genomes of pathogens using a BCG recombinant system

Prevention